Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717593 | 0.83 | TRPM8 (0.37) | TRPM8KDM4EATMALDH1A1TEAD1 | |
| SCHEMBL17076138 | 0.74 | ATM (0.40) | TRPM8KDM4EATMALDH1A1L3MBTL1 | |
| SCHEMBL17076139 | 0.74 | ATM (0.40) | TRPM8KDM4EATMALDH1A1L3MBTL1 | |
| SCHEMBL6716842 | 0.73 | CYP1A2 (0.48) | ALDH1A1GAALMNACYP3A4 | |
| SCHEMBL6716835 | 0.73 | CYP1A2 (0.48) | ALDH1A1GAALMNACYP3A4 | |
| SCHEMBL11402402 | 0.73 | TRPM8 (0.49) | TRPM8ALDH1A1TEAD1GAALMNA | |
| SCHEMBL17075966 | 0.72 | ATM (0.40) | KDM4EATMALDH1A1L3MBTL1GAA | |
| SCHEMBL17075965 | 0.72 | ATM (0.40) | KDM4EATMALDH1A1L3MBTL1GAA | |
| SCHEMBL6715727 | 0.72 | SLC6A2 (0.38) | TRPM8ALDH1A1SLC6A2SLC6A4L3MBTL1 | |
| SCHEMBL6717632 | 0.72 | ATM (0.47) | ATMALDH1A1GAALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | TRPM8 1323/4885KDM4E 3734/4885ATM 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.